QATARI GERMAN FOR MEDICAL DEVICES COMPANY (Q.P.S.C)

INVESTOR RELATIONS CONFERENCE CALL

ON

15TH NOVEMBER 2026

TO DISCUSS THE FINANCIAL RESULTS

FOR

Q3-2026

ENDED 30TH SEPTEMBER 2026

www.qgmd.com

Company Overview

- QGMD is one of the leading manufacturers of Medical Devices in the Middle East ,Headquartered in Doha, Qatar.
- QG Medical Devices Co. was established in the year 2000 to produce high quality medical devices in Qatar; utilizing best of breed technology and machines.
- QG Medical Devices is a Public Listed Company in Qatar Stock Exchange.



QGMD Production Facilities and Machineries

QG Medical Devices is equipped with state of art production facility designed by reputable innovative European technology providers .





INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30th, 2026



STATEMENT OF FINANCIAL POSITION AS SEPTEMBER 30th, 2026

	Notes	30 September 2026 (Reviewed)	31 December 2025 (Audited)
Assets			
Non-current assets			
Property, plant and equipment	4	92,239,341	95,617,788
Intangible assets	5	8,223,245	8,223,245
Right-of-use assets		44,142	51,112
Investment properties	6	12,441,000	12,441,000
		112,947,728	**116,333,145**
Current assets			
Inventories	7	14,617,587	15,410,162
Trade and other receivables	8	4,071,009	2,357,023
Cash and bank balances	10	102,058	638,343
		18,790,654	**18,405,528**
Total assets		**131,738,382**	**134,738,673**
Equity and liabilities			
Equity			
Share capital	11	115,500,000	115,500,000
Legal reserve		31,735,090	31,735,090
Revaluation reserve		12,151,865	12,151,865
Accumulated losses		(184,230,730)	(182,795,834)
		(24,843,775)	**(23,408,879)**
Non-current liabilities			
Employee terminal benefits	12	338,894	369,150
Lease liabilities		32,662	43,074
Borrowings	13	132,441,598	136,098,876
		132,813,154	**136,511,100**
Current liabilities			
Lease liabilities		10,045	9,874
Borrowings	13	9,162,419	5,826,063
Trade and other payables	14	14,596,539	15,800,515
		23,769,003	**21,636,452**
Total liabilities		**156,582,157**	**158,147,552**
Total equity and liabilities		**131,738,382**	**134,738,673**

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE NINE MONTHS ENDED SEPTEMBER 30th, 2026

	Notes	For the three-month period ended 30 September		For the nine-month period ended 30 September	
		2026 (Reviewed)	2025 (Unreviewed)	**2026 (Reviewed)**	2025 (Unreviewed)
Income					
Revenue	15	1,807,077	1,243,173	4,552,387	3,016,785
Cost of sales	16	(637,057)	(918,684)	(2,357,395)	(2,333,340)
Gross profit		**1,170,020**	**324,489**	**2,194,992**	**683,445**
Other income	17	635,520	691,863	2,220,330	1,991,035
Gain on restructuring of borrowing	13	-	-	-	9,585,423
		1,805,540	**1,016,352**	**4,415,322**	**12,259,903**
Expenses					
General and administrative expenses	18	(1,730,290)	(1,573,595)	(5,124,731)	(5,508,588)
Selling and distribution expenses		(10,076)	(6,343)	(93,921)	(53,216)
Finance costs		(265,939)	(229,154)	(631,566)	(1,713,912)
		(2,006,305)	**(1,809,092)**	**(5,850,218)**	**(7,275,716)**
(Loss) / Profit for the period		**(200,765)**	**(792,740)**	**(1,434,896)**	**4,984,187**
Other comprehensive income for the period		-	-	-	-
Total comprehensive (loss) / income for the period		**(200,765)**	**(792,740)**	**(1,434,896)**	**4,984,187**
Basic and diluted (loss) / earnings per share	19	(0.002)	(0.007)	(0.012)	0.043

Q&A Session

If anyone has any questions regarding the financial results, please feel free to ask.

Thank you

Qatari German for Medical Devices

www.qgmd.com

